BMS-986353 Clinical Trials (2026): 1 Studies for Systemic Sclerosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 BMS-986353 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Systemic Sclerosis) and 92 total planned enrollment. 1 Phase 3 BMS-986353 trial are listed. 1 BMS-986353 clinical trial is actively recruiting. Most recent activity: NCT07335562 (Nov 2030).
BMS-986353 clinical trials at a glance: phase × recruitment status
| Phase | not yet recruiting | Total |
|---|---|---|
| P3 | 1 | 1 |
Recruiting BMS-986353 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07335562 | Breakfree-SScA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis | P3 | Systemic Sclerosis | 92 | Aug 2026 |
BMS-986353 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| Breakfree-SSc | NCT07335562 | P3 | not yet recruiting | Systemic Sclerosis | 92 | — |
All BMS-986353 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07335562 | Breakfree-SSc | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis | P3 | not yet recruiting | 92 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Aug 2026 |
BMS-986353 clinical trials: frequently asked questions
- How many BMS-986353 clinical trials are there?
- 1 BMS-986353 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are BMS-986353 clinical trials recruiting in 2026?
- No active BMS-986353 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is BMS-986353 being studied for?
- BMS-986353 is being studied for Systemic Sclerosis. The trials are grouped by indication on this page.
- What phase is BMS-986353 in?
- BMS-986353 clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BMS-986353 clinical trials?
- The lead sponsor across the most BMS-986353 trials is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BMS-986353as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: